Center for Molecular Innovation, Feinstein Institute of Bioelectronic Medicine Feinstein Institutes for Medical Research, Northwell Health 350 Community Drive, Manhasset, NY 11030, USA.
Robert S. Boas Center for Genomics & Human Genetics, Feinstein Institute of Molecular Medicine Feinstein Institutes for Medical Research, Northwell Health 350 Community Drive, Manhasset, NY 11030, USA.
Future Med Chem. 2020 Sep;12(18):1647-1656. doi: 10.4155/fmc-2020-0180. Epub 2020 Jul 16.
During a disease outbreak/pandemic situation such as COVID-19, researchers are in a prime position to identify and develop peptide-based therapies, which could be more rapidly and cost-effectively advanced into a clinical setting. One drawback of natural peptide drugs, however, is their proteolytic instability; peptidomimetics can help to overcome this caveat. In this review, we summarize peptide and peptide-based therapeutics that target one main entry pathway of SARS-CoV-2, which involves the host ACE2 receptor and viral spike (S) protein interaction. Furthermore, we discuss the advantages of peptidomimetics and other potential targets that have been studied using peptide-based therapeutics for COVID-19.
在 COVID-19 等疾病爆发/大流行期间，研究人员处于识别和开发基于肽的疗法的最佳位置，这些疗法可以更快速、更具成本效益地推进到临床环境中。然而，天然肽类药物的一个缺点是其蛋白水解不稳定；肽模拟物可以帮助克服这一缺点。在这篇综述中，我们总结了针对 SARS-CoV-2 主要进入途径的肽和基于肽的治疗方法，该途径涉及宿主 ACE2 受体和病毒刺突 (S) 蛋白相互作用。此外，我们讨论了使用基于肽的治疗方法治疗 COVID-19 时，肽模拟物和其他潜在靶点的优势。
